Article
Intracranial effect of osimertinib in relapsed EGFR-mutated T790M-positive and -negative non-small cell lung cancer patients: results from a phase II study.
Acta oncologica (Stockholm, Sweden) - 1 Dec 2021
Eide Inger Johanne Zwicky, Grut Harald, Helland Åslaug, Ekman Simon, Sørensen Jens Benn, Hansen Karin Holmskov, Grønberg Bjørn Henning, Cicenas Saulius, Koivunen Jussi Pekka, Mellemgaard Anders, Brustugun Odd Terje
Abstract excerpt
INTRODUCTION: Osimertinib is effective for relapsed T790M-positive patients with brain metastases. The high brain permeability suggests that also such patients without T790M could benefit. Therefore, we evaluated the effect of osimertinib on brain metastases in both T790M-positive and -negative patients. METHODS: The TREM-study was an investigator-initiated phase II, single-arm, multi-institutional clinical trial...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.